- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00420719
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
Multi-Center Pivotal Study of Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
The overall goal of this research is to delay the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically placed electrodes.
This device currently holds an Investigational Device Exemption No. G040142 in the United States and is currently undergoing clinical trials at University Hospitals (Cleveland), Johns Hopkins, Mayo Clinic Jacksonville, California Pacific Medical Center (CPMC), Henry Ford Health System, The Methodist Hospital, and Stanford University.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to demonstrate the safety and efficacy of the NeuRX RA/4 Diaphragm Pacing Stimulation (DPS) System in conditioning the diaphragm of an ALS patient to improve the quality of life and slow the progression to respiratory failure.
Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease or Motor Neuron Disease) is a progressive neurodegenerative disease of unknown cause. One of the most important effects of progressive neuromuscular weakness in patients with ALS is the effect on respiration. Although ALS has no direct effect on the lung, it has devastating effects on mechanical function of the respiratory system. ALS affects all of the major respiratory muscle groups: upper airway muscles, expiratory muscles, and inspiratory muscles. Therefore, all patients with ALS are at significant risk for respiratory complications. Progressive inspiratory muscle weakness in ALS inevitably leads to carbon dioxide retention, inability to clear secretions and hypercarbic respiratory failure, the major cause of death in ALS.
Synapse Biomedical, in conjunction with Case Western Reserve University and University Hospitals of Cleveland, have evaluated activating the diaphragm with percutaneous intramuscular electrodes implanted laparoscopically. This eliminates any direct contact with the phrenic nerve, allows all circuitry and electronics to remain outside the body, and provides direct, selective activation to each hemidiaphragm. The NeuRx-RA/4 DPS System provides an electrical signal to the motor point of the muscle that causes the diaphragm to contract and allows patients to breathe more naturally.
The NeuRx RA/4 DPS System has been implanted in over 10 individuals with ALS, in a pilot study at the University Hospitals of Cleveland that began January, 2005.
The NeuRx RA/4 DPS System platform, also used for respiratory support for individuals with high-level spinal cord injury, has over 56 years of cumulative active implantation time. The longest term patient was implanted March 6, 2000 and has been using the DPS System as his sole means of respiratory support for over six years.
Given patient results to date the data supports safety and efficacy to proceed to pivotal study in this patient population. With no unexpected significant adverse events reported, the NeuRx RA/4 DPS System has performed reliably and safely.
Device Description: The NeuRx RA/4 Respiratory System is manufactured by Synapse Biomedical. The NeuRx RA/4 System comprises the following components: an external, battery powered Stimulator Device, an associated Programmer/Controller, Intramuscular Electrodes, associated percutaneous Lead Wires, a Surgical Placement Tool Set, and a surgical Mapping Station.
Inclusion Criteria:
- Age 18 or older
- Participants with familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria will be eligible
- Bilateral phrenic nerve function clinically acceptable as demonstrated by bilateral diaphragm movement with fluoroscopic sniff test or with EMG recordings and nerve conduction times
- Forced Vital Capacity (FVC) between 50 - 85% of predicted values to begin screening procedures.
- FVC greater than 45% of predicted value at time of surgery.
- No underlying cardiac or pulmonary diseases that would increase the risk of general anesthesia greater than the expected risk of the patient with ALS
- Negative pregnancy test in females of child-bearing potential
- Informed consent from patient or designated representative
Exclusion Criteria:
- Preexisting implanted electrical device such as pacemaker or cardiac defibrillator.
- Underlying pulmonary diseases that were present prior to ALS that would effect pulmonary tests independent of ALS.
- Active cardiovascular disease that would increase the risk of general anesthesia
- Current pregnancy or breastfeeding
- Hospitalization for a treated active infection within the last 2 months
- Significant decision making incapacity preventing informed consent by the subject due to a major mental disorder such as major depression or schizophrenia, or dementia such as having Alzheimer's disease.
- Marked obesity
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
California
-
San Francisco, California, United States, 94115
- Forbes Norris - California Pacific Medical Center (CPMC)
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Michigan
-
Detroit, Michigan, United States, 48202-2689
- Henry Ford Health System
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older
- Participants with familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria will be eligible
- Bilateral phrenic nerve function clinically acceptable as demonstrated by bilateral diaphragm movement with fluoroscopic sniff test or with EMG recordings and nerve conduction times
- Forced Vital Capacity (FVC) between 50 - 85% of predicted values to begin screening procedures.
- FVC greater than 45% of predicted value at time of surgery.
- No underlying cardiac or pulmonary diseases that would increase the risk of general anesthesia greater than the expected risk of the patient with ALS
- Negative pregnancy test in females of child-bearing potential
- Informed consent from patient or designated representative
Exclusion Criteria:
- Preexisting implanted electrical device such as pacemaker or cardiac defibrillator.
- Underlying pulmonary diseases that were present prior to ALS that would effect pulmonary tests independent of ALS
- Active cardiovascular disease that would increase the risk of general anesthesia
- Current pregnancy or breastfeeding
- Hospitalization for a treated active infection within the last 2 months
- Significant decision making incapacity preventing informed consent by the subject due to a major mental disorder such as major depression or schizophrenia, or dementia such as having Alzheimer's disease.
- Marked obesity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The DPS System will slow the decline of pulmonary function, as defined by percent predicted forced vital capacity (FVC) to 30% of normal, by approximately 12 months
Time Frame: After completion of the study
|
After completion of the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events from implantation and use of the DPS System will be logged and qualitatively compared to adverse event rates in similar patient populations.
Time Frame: After completion of the study
|
After completion of the study
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN 20-0009-0005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis (ALS)
-
Northwestern UniversityCompletedAmyotrophic Lateral Sclerosis (ALS) | Lou Gehrig's Disease | Primary Lateral Sclerosis (PLS) | Familial Amyotrophic Lateral Sclerosis | ALS With Frontotemporal Dementia (ALS/FTD) | Motor Neuron Disease (MND) | Sporadic ALS (SALS)United States
-
Dallas VA Medical CenterRecruitingAmyotrophic Lateral Sclerosis (ALS)United States
-
St. Joseph's Hospital and Medical Center, PhoenixEmory University; Mitsubishi Tanabe Pharma America Inc.Active, not recruitingALS (Amyotrophic Lateral Sclerosis)United States
-
Taipei Veterans General Hospital, TaiwanUnknownDevelopment and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.ALS (Amyotrophic Lateral Sclerosis)Taiwan
-
Brainstorm-Cell TherapeuticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Phoenix Neurological Associates, LTDInstitute for EthnomedicineUnknown
-
Skulpt, Inc.National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
Clinical Trials on Intramuscular diaphragm electrodes
-
University of MichiganUnited States Department of DefenseRecruitingAmputation | Prostheses and ImplantsUnited States
-
Louis Stokes VA Medical CenterUnited States Department of Defense; Case Western Reserve UniversityRecruiting
-
US Department of Veterans AffairsCompleted
-
US Department of Veterans AffairsCompleted
-
Università Vita-Salute San RaffaeleCompleted
-
University Medical Center NijmegenUnknownSepsis | Mechanical VentilationNetherlands
-
Leiden University Medical CenterRecruitingUltrasound | Diaphragm | Neonate | Transcutaneous EMGNetherlands
-
Helga Cecília Muniz de SouzaUniversidade Federal de PernambucoCompleted
-
Universidade Federal de PernambucoUnknownCopd | Diaphragmatic Disorder | Chest DisordersBrazil
-
Daniella Cunha BrandaoCompleted